β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

(2014) E. Traer et al.   BLOOD

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

(2014) A M Eiring et al.   LEUKEMIA

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling

(2013) B. Zhang et al.   BLOOD

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Cross talk between Wnt/β-catenin andIrf8in leukemia progression and drug resistance

(2013) Marina Scheller et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function

(2013) S. Lim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression

(2012) Christian Schürch et al.   JOURNAL OF CLINICAL INVESTIGATION

Wnt5a: its signalling, functions and implication in diseases

(2011) A. Kikuchi et al.   Acta Physiologica

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts

(2011) Y Tabe et al.   LEUKEMIA

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

(2011) E Traer et al.   LEUKEMIA

Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis

(2011) Michael A. Dengler et al.   PLoS One

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

(2010) F. Vianello et al.   HAEMATOLOGICA

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Interferon Consensus Sequence Binding Protein (ICSBP) Decreases  -Catenin Activity in Myeloid Cells by Repressing GAS2 Transcription

(2010) W. Huang et al.   MOLECULAR AND CELLULAR BIOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

(2009) S. K. McWeeney et al.   BLOOD

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

(2009) Yaoyu Chen et al.   NATURE GENETICS

Glycogen synthase kinase 3  missplicing contributes to leukemia stem cell generation

(2009) A. E. Abrahamsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interplay of Cadherin-Mediated Cell Adhesion and Canonical Wnt Signaling

(2009) J. Heuberger et al.   Cold Spring Harbor Perspectives in Biology

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

(2008) Nadine N. Bewry et al.   MOLECULAR CANCER THERAPEUTICS